Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Raquel Lahoz, Divyagiri Seshagiri, Batul Electricwala, Assya Achouba, Yingjie Ding, Ji Haeng Heo, Joaquim Cristino & Rachel Studer. (2023) Clinical characteristics and treatment patterns in patients with atherosclerotic cardiovascular disease with hypercholesterolemia: a retrospective analysis of a large US real-world database cohort. Current Medical Research and Opinion 0:0, pages 1-11.
Read now
Read now
Constantine E Kosmas, Andreas Skavdis, Andreas Sourlas, Evangelia J Papakonstantinou, Edilberto Peña Genao, Rogers Echavarria Uceta & Eliscer Guzman. (2020) Safety and Tolerability of PCSK9 Inhibitors: Current Insights. Clinical Pharmacology: Advances and Applications 12, pages 191-202.
Read now
Read now
Sheila A. Doggrell. (2020) Inclisiran, the billion-dollar drug, to lower LDL cholesterol – is it worth it?. Expert Opinion on Pharmacotherapy 21:16, pages 1971-1974.
Read now
Read now
Articles from other publishers (25)
Alissia Stummer, Robin Ristl, Bernhard Kogler, Melanie Muskovich, Michael Kossmeier & Thomas M. Stulnig. (2023) Patient adherence to fully reimbursed proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) treatment. Wiener klinische Wochenschrift 135:13-14, pages 375-382.
Crossref
Crossref
Jessica Eloso, Asma Awad, Xinhua Zhao, Francesca E. Cunningham, Rongping Zhang, Diane Dong, Cathy Kelley, Peter A. Glassman & Sherrie L. Aspinall. (2023) PCSK9 Inhibitor Use and Outcomes Using Concomitant Lipid-Lowering Therapies in the Veterans Health Administration. American Journal of Medicine Open 9, pages 100035.
Crossref
Crossref
Salil V. Deo, David McAllister, Sharon LaForest, Salah Altarabsheh, Yakov E. Elgudin, Shannon Dunlay, Simerpreet Singh, Sahil Parikh, Naveed Sattar & Jill P. Pell. (2023) Disparities in PCSK9 Initiation Among US Veterans with Peripheral Arterial Disease or Cerebrovascular Disease. American Journal of Cardiovascular Drugs 23:3, pages 311-321.
Crossref
Crossref
Anastasia V. Poznyak, Vasily N. Sukhorukov, Ilya I. Eremin, Irina I. Nadelyaeva, Nikita A. Gutyrchik & Alexander N. Orekhov. (2023) Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis. Biomedicines 11:2, pages 503.
Crossref
Crossref
Kausik K. Ray, Eric Bruckert, Pasquale Peronne-Filardi, Christoph Ebenbichler, Anja Vogt, Ian Bridges, Mahendra Sibartie & Nafeesa Dhalwani. (2023) Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: Final results from the European observational HEYMANS study. Atherosclerosis 366, pages 14-21.
Crossref
Crossref
Paola Gargiulo, Christian Basile, Arturo Cesaro, Federica Marzano, Davide Buonocore, Gaetano Asile, Vincenza Abbate, Francesca Vicidomini, Stefania Paolillo, Carmen Anna Maria Spaccarotella, Angelo Catalano, Giulio Spirito, Piera Angelica Merlini, Alessandro Maloberti, Gabriella Iannuzzo, Marco Matteo Ciccone, Anna Paola Zito, Leonardo Paloscia, Alberto D'Alleva, Ferdinando Varbella, Antonella Corleto, Natale Daniele Brunetti, Maria Delia Corbo, Paolo Calabrò, Ciro Indolfi & Pasquale Perrone-Filardi. (2023) Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: A single country, multicenter, observational study (AT-TARGET-IT). Atherosclerosis 366, pages 32-39.
Crossref
Crossref
Avishay Elis, Cheli Melzer Cohen & Gabriel Chodick. (2023) Real-World Use of Alirocumab: Experience from a Large Healthcare Provider. Journal of Clinical Medicine 12:3, pages 1084.
Crossref
Crossref
Toshiyuki Nishikido. (2023) Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease. Cardiovascular Diabetology 22:1.
Crossref
Crossref
William Bruce Wong, Arpamas Seetasith, Anna Hung & Leah L. Zullig. (2023) Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs. PLOS ONE 18:1, pages e0280570.
Crossref
Crossref
Nihar R. Desai, Michael Farbaniec & Dean G. Karalis. (2022) Nonadherence to lipid‐lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease. Clinical Cardiology 46:1, pages 13-21.
Crossref
Crossref
S. K. Zyryanov & O. I. Butranova. (2022) New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy. Russian Journal of Cardiology 27:11, pages 5271.
Crossref
Crossref
Ahmed Shawky Elserafy, Ahmed Bendary, Atef Elbahry, Elsayed Farag, Tamer Mostafa, Osama Sanad, Ahmed Elkersh, Mohammed Selim, Hany Ragy, Hazem Khamis, Waleed Abdo & Ashraf Reda. (2022) The Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) Perspectives on the Usage of Inclisiran. Cardiology and Therapy 11:4, pages 461-471.
Crossref
Crossref
Natalie Arnold & Wolfgang Koenig. (2022) PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection. Current Cardiology Reports 24:11, pages 1657-1667.
Crossref
Crossref
Angela Pirillo & Alberico Luigi Catapano. (2022) Inclisiran: How Widely and When Should We Use It?. Current Atherosclerosis Reports 24:10, pages 803-811.
Crossref
Crossref
Dustin R. Donald, Victoria W. Reynolds, Nicole Hall, Josh DeClercq & Leena Choi. (2022) Exploring rates of PCSK9 inhibitor persistence and reasons for treatment non-persistence in an integrated specialty pharmacy model. Journal of Clinical Lipidology 16:3, pages 315-324.
Crossref
Crossref
Sara N. Levintow, Kate K. Orroth, Alexander Breskin, Andrew S. Park, Jose H. Flores‐Arredondo, Paul Dluzniewski, Ann Marie Navar, Henrik T. Sørensen & M. Alan Brookhart. (2021) Use of negative control outcomes to assess the comparability of patients initiating lipid‐lowering therapies. Pharmacoepidemiology and Drug Safety 31:4, pages 383-392.
Crossref
Crossref
EC McKinley, VA Bittner, TM Brown, L Chen, LD Colantonio, J Exter, KK Orroth, SR Reading, RS Rosenson & P Muntner. (2022) Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction. Journal of Clinical Lipidology 16:1, pages 75-82.
Crossref
Crossref
Xue Feng, Flora Berklein, Pallavi B. Rane, Mohdhar Habib & Pei-Jung Lin. (2020) Patient Characteristics and Treatment Patterns among Medicare Beneficiaries Initiating PCSK9 Inhibitor Therapy. Cardiovascular Drugs and Therapy 35:5, pages 965-973.
Crossref
Crossref
Julia Brandts & Kausik K Ray. (2021) Clinical implications and outcomes of the ORION Phase III trials. Future Cardiology 17:5, pages 769-777.
Crossref
Crossref
Kiran Musunuru, Alexandra C. Chadwick, Taiji Mizoguchi, Sara P. Garcia, Jamie E. DeNizio, Caroline W. Reiss, Kui Wang, Sowmya Iyer, Chaitali Dutta, Victoria Clendaniel, Michael Amaonye, Aaron Beach, Kathleen Berth, Souvik Biswas, Maurine C. Braun, Huei-Mei Chen, Thomas V. Colace, John D. Ganey, Soumyashree A. Gangopadhyay, Ryan Garrity, Lisa N. Kasiewicz, Jennifer Lavoie, James A. Madsen, Yuri Matsumoto, Anne Marie Mazzola, Yusuf S. Nasrullah, Joseph Nneji, Huilan Ren, Athul Sanjeev, Madeleine Shay, Mary R. Stahley, Steven H. Y. Fan, Ying K. Tam, Nicole M. Gaudelli, Giuseppe Ciaramella, Leslie E. Stolz, Padma Malyala, Christopher J. Cheng, Kallanthottathil G. Rajeev, Ellen Rohde, Andrew M. Bellinger & Sekar Kathiresan. (2021) In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 593:7859, pages 429-434.
Crossref
Crossref
Catherine G. Derington, Lisandro D. Colantonio, Jennifer S. Herrick, James Cook, Jordan B. King, Robert S. Rosenson, Bharat Poudel, Keri L. Monda, Ann Marie Navar, Katherine E. Mues, Vanessa W. Stevens, Richard E. Nelson, Megan E. Vanneman, Paul Muntner & Adam P. Bress. (2021) Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans. Journal of the American Heart Association 10:8.
Crossref
Crossref
Barak Zafrir, Aya Egbaria, Nili Stein, Avishay Elis & Walid Saliba. (2021) PCSK9 inhibition in clinical practice: Treatment patterns and attainment of lipid goals in a large health maintenance organization. Journal of Clinical Lipidology 15:1, pages 202-211.e2.
Crossref
Crossref
Vivencio Barrios, Carlos Escobar, Vicente Arrarte, Eusebio García, María Rosa Fernández, Luis Miguel Rincón & Cecilia Roldán. (2020) Primer registro nacional sobre la efectividad y seguridad de evolocumab en la práctica clínica en pacientes atendidos en cardiología en España. Estudio RETOSS-CARDIO. Clínica e Investigación en Arteriosclerosis 32:6, pages 231-241.
Crossref
Crossref
Vivencio Barrios, Carlos Escobar, Vicente Arrarte, Eusebio García, María Rosa Fernández, Luis Miguel Rincón & Cecilia Roldán. (2020) First national registry on the effectiveness and safety of evolocumab in clinical practice in patients attended in cardiology in Spain. The RETOSS-CARDIO study. Clínica e Investigación en Arteriosclerosis (English Edition) 32:6, pages 231-241.
Crossref
Crossref
Carlo Piccinni, Ippazio Cosimo Antonazzo, Aldo P. Maggioni, Antonella Pedrini, Silvia Calabria, Giulia Ronconi, Letizia Dondi, Nello Martini, Giuseppe Roberto, Tiziana Sampietro, Francesco Sbrana, Beatrice Dal Pino, Federico Bigazzi, Giuseppa Lo Surdo, Elisabetta Volpi, Stefania Biagini & Rosa Gini. (2019) PCSK9 Inhibitors’ New Users: Analysis of Prescription Patterns and Patients’ Characteristics from an Italian Real-world Study. Clinical Drug Investigation 40:2, pages 173-181.
Crossref
Crossref